Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder

Toxins (Basel). 2016 May 30;8(6):164. doi: 10.3390/toxins8060164.

Abstract

Chornic spinal cord injury (SCI) will induce bladder urothelium dysfunction. This study investigated the therapeutic effects on urothelial dysfunction after repeated detrusor injections of onabotulinumtoxinA (BoNT-A) in SCI patients with neurogenic detrusor overactivity (NDO). Twenty chronic suprasacral SCI patients with NDO were enrolled. The patients received 300 U BoNT-A injection into the detrusor every six months. The urothelium was assessed by cystoscopic biopsy at baseline and six months after each BoNT-A treatment. Immunofluorescence staining for urothelial dysfunction, including E-cadherin, zonula occludens-1 (ZO-1), tryptase for mast cell activity, and urothelial apoptosis were investigated. The outcome of urothelial dysfunction parameters after BoNT-A injection were compared between baseline and six months after each treatment. Repeated 300 U BoNT-A injections showed a sustained decrease of detrusor pressure compared with baseline. After three repeated BoNT-A detrusor injections, significantly greater distributions of E-cadherin (p = 0.042) and ZO-1 (p = 0.003) expressions, but no significant changes, of urothelial apoptosis and mast cell activation were found after repeated BoNT-A therapy. Urothelial dysfunction, such as adhesive and junction protein concentrations in SCI patients' bladders, recovered after three repeated cycles of BoNT-A treatment. The therapeutic effects sustained. However, urothelial inflammation and apoptosis after SCI were not significantly improved after three repeated BoNT-A injections.

Keywords: botulinum toxin A; spinal cord injury; urothelial dysfunction.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antigens, CD
  • Apoptosis / drug effects
  • Botulinum Toxins, Type A / pharmacology
  • Botulinum Toxins, Type A / therapeutic use*
  • Cadherins / metabolism
  • Female
  • Humans
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Muscle, Smooth
  • Neuromuscular Agents / pharmacology
  • Neuromuscular Agents / therapeutic use*
  • Spinal Cord Injuries / complications*
  • Treatment Outcome
  • Urinary Bladder, Neurogenic / drug therapy*
  • Urinary Bladder, Neurogenic / metabolism
  • Urinary Bladder, Neurogenic / physiopathology
  • Urinary Bladder, Overactive / drug therapy*
  • Urinary Bladder, Overactive / metabolism
  • Urinary Bladder, Overactive / physiopathology
  • Urodynamics
  • Urothelium / drug effects
  • Urothelium / metabolism
  • Urothelium / physiology
  • Zonula Occludens-1 Protein / metabolism

Substances

  • Antigens, CD
  • CDH1 protein, human
  • Cadherins
  • Neuromuscular Agents
  • TJP1 protein, human
  • Zonula Occludens-1 Protein
  • Botulinum Toxins, Type A